A retrospective study of long-term outcomes in 152 patients with primary Sjögren's syndrome: 25-year experience The objective of this study was to evaluate the 25-year outcome of patients with primary Sjögren's syndrome (pSS). One hundred and fi fty-two patients diagnosed with pSS (American-European classifi cation criteria) were retrospectively and descriptively analysed
IntroductionSjögren's syndrome (SS) is a systemic autoimmune epithelitis. 1 It affects approximately 0.5% of the general population, 2,3 making it one of the most prevalent systemic autoimmune diseases, second only to rheumatoid arthritis. 4 One of the most welldescribed risks to patients with SS is the development of nonHodgkin's lymphoma (NHL), the lifetime probability of which has been reported to be between 5% and 15%, 5 or 20-fold higher than in the general population. 3 In primary Sjögren's syndrome These include other types of malignancies, other autoimmune diseases, 6 vasculitis 7 and haematological disorders. 8,9 Sinister complications such as the malignancies are typically late events whereas other complications accumulate over time. 10 The aim of this study was to analyse the demographic, serological, immunological and phenotypic characteristics of 152 patients followed up in the Centre for Rheumatology, University College Hospital, London, over a long-term follow-up.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.